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Context: Autoimmune hypocalciuric hypercalcemia (AHH) is an acquired disorder 24 
caused by the presence of blocking autoantibodies against the calcium-sensing receptor 25 
(CaSR). Few cases of this condition have been described to date in the literature. 26 
Objective: The objectives of this study were to describe two patients in whom the 27 
presence of AHH was suspected and to assess the patients for the presence of CaSR 28 
antibodies. 29 
Methods: CaSR antibodies were detected and characterised by immunoprecipitation 30 
assays, CaSR peptide ELISAs, and functional assays based on the calcium-stimulated 31 
accumulation of inositol-1-phosphate in a mammalian cell line expressing the CaSR. 32 
Results: Both patients presented with an acquired form of hypocalciuric hypercalcemia. 33 
Mutational analyses of CASR, GNA11 and AP2S1 for familial hypocalciuric 34 
hypercalcemia, were negative. According to the presence of Hashimoto’s disease in one  35 
patient and latent autoimmune diabetes of adulthood and thyroid autoimmunity in the 36 
other, AHH was suspected. Immunoprecipitation assays detected CaSR antibodies in both 37 
patients. Analysis of the antibody binding sites revealed two main epitopes at amino acids 38 
41-69 and 114-126. Preincubation with purified CaSR antibodies against epitope 114-126 39 
resulted in a significant decrease in inositol-1-phophate accumulation upon calcium-40 
stimulation of mammalian cells expressing the CaSR, suggesting that the antibodies had 41 
receptor-blocking activity. 42 
Conclusions: AHH is to be suspected in patients with an acquired biochemical pattern of 43 




autoimmune diseases. Diagnosis by means of detecting CaSR antibodies may help to 45 






The calcium-sensing receptor (CaSR) is a G protein–coupled receptor that regulates 49 
parathyroid hormone (PTH) secretion from the parathyroid glands by responding to 50 
extracellular levels of calcium (1-3). Increases in extracellular calcium levels activate the 51 
CaSR to inhibit PTH secretion, while decreases inhibit the receptor such that PTH release 52 
is elevated (1-3). Functionally, PTH upregulates calcium resorption from the bone and 53 
downregulates phosphate excretion from the kidneys thereby increasing and decreasing 54 
serum calcium and phosphate, respectively (1-3). The CaSR is also expressed in the 55 
kidneys where it enhances urinary calcium excretion in response to high levels of the 56 
analyte independently of concomitant receptor-mediated changes in the level of 57 
circulating PTH (2, 3). Thus, regulation of blood calcium is tightly controlled so that its 58 
concentration is held within strict limits. 59 
Homozygous mutations that inactivate the CaSR prevent feedback inhibition of the 60 
parathyroid by extracellular calcium causing markedly elevated PTH levels and 61 
hypercalcemia, a disorder known as neonatal severe hyperparathyroidism (4, 5). 62 
Heterozygous mutations of the receptor lead the condition referred to as familial 63 
hypocalciuric hypercalcemia (FHH) (4, 5). Such mutations decrease the CaSR’s 64 
sensitivity to calcium, resulting in reduced receptor stimulation at normal blood calcium 65 
levels. As a result, inhibition of PTH secretion does not occur until higher serum calcium 66 
levels are reached and reabsorption of renal calcium also continues. Thus, individuals 67 
with FHH have PTH-dependent hypercalcemia with a normal or modestly elevated PTH 68 
level as well as inappropriately normal or frankly low urinary calcium excretion, the 69 




addition to the CASR, mutations in the AP2S1 (encodes adaptor protein-2 σ subunit) and 71 
GNA11 (encodes G-protein subunit α11) genes can also results in FHH, but these are less 72 
common causes (9-11). 73 
An acquired form of hypercalcemia accompanied by hypocalciuria, caused by antibodies 74 
that blocked the CaSR thus preventing it from reacting to elevated calcium, was first 75 
described by Kifor and colleagues (12). Referred to as autoimmune hypocalciuric 76 
hypercalcemia (AHH), the condition mimicked the biochemical pattern observed in 77 
patients with FHH, but was also in the setting of various other autoimmune disorders 78 
(12). Since this first report of AHH, only a few new cases have been highlighted (13-18). 79 
Herein, we present two patients with hypercalcemia and low urinary calcium:creatinine 80 
clearance ratios (UCCR), where the presence of AHH was suspected as both individuals 81 
displayed autoimmune manifestations. In order to clarify the aetiology, the patients were 82 
assessed for CaSR antibodies that might inhibit the receptor causing elevated levels of 83 





Patients and methods 86 
Case presentations 87 
Patient 1 was a 66-year-old male that came to our clinic in 2012 for adjustment of his 88 
levothyroxine treatment. He had Hasimoto’s thyroiditis, but no other autoimmune 89 
diseases. During follow-up, levothyroxine was adjusted in order to maintain a normal 90 
thyroid-stimulating hormone (TSH) level, but an assymptomatic hypercalcemia was 91 
detected where previously the patient had had normal blood calcium concentrations. 92 
Since then, all tests performed showed persistent hypercalcemia with albumin-adjusted 93 
serum calcium levels of  2.68-2.70 mmol/L (normal range, 2.15-2.55 mmol/L) (Figure 1), 94 
constant hypocalciuria with a low UCCR of < 0.01 (normal range, 0.01-0.02) (Figure 1), 95 
and decreased serum phosphate levels of 0.73-0.87 mmol/L (normal range, 0.87-1.45 96 
mmol/L). Magnesium levels were normal at 0.93-1.0 mmol/L (normal range, 0.65-1.05 97 
mmol/L). PTH levels were elevated and ranged from 18-36 pmol/L (normal range, 1.3-98 
6.8 pmol/L) and glomerular filtration rate (GFR) was normal at >60 mL/min/1.73m2. 99 
The patient had no history of personal or familial hypercalcaemia and mutational 100 
analyses of CASR, GNA11 and AP2S1 were negative. Sestamibi scan showed no evidence 101 
of hyperfunctioning parathyroid glands. Autoimmunity studies performed in January 102 
2015 showed positivity for thyroid peroxidase (TPO) antibodies at 462 IU/mL (normal 103 
range, <100 IU/mL), perinuclear anti-neutrophil cytoplasmic antibodies, anti-104 
mitochondrial antibodies at a 1:160 titre (normal range, titre of < 1:80), and anti-105 
mitochondrial M2 antibody. A bone densitometry analysis perfomed in 2015 revealed 106 




calcium levels. At his last visit the patient was treated with levothyroxine, cholecalciferol, 108 
alendronate, amlodipine, and telmisartan as he was diagnosed with hypertension during 109 
follow-up. 110 
Patient 2 was a 51-year-old male with hypercalcemia since 2008, but who previous to that 111 
had normal calcium levels. Maximal albumin-adjusted calcium levels were high at 2.67 112 
mmol/L (Figure 1), UCCR oscilated between 0.0022 and 0.130 (Figure 1), and phosphate 113 
concentrations were normal at 1.39-1.45 mmol/L. Magnesium levels were normal 0.74 114 
mmol/L. PTH was repeatedly normal at 2.1-3.0 pmol/L and GFR was normal at >60 115 
mL/min/1.73m2. 116 
Sestamibi scan showed no evidence of hyperfunctioning parathyroid glands. The patient 117 
had no family or personal history of calcium disorders and mutational analyses of the 118 
CASR, GNA11 and AP2S1 genes were negative. He had latent autoimmune diabetes of 119 
adulthood (LADA) treated with insulin glargine and aspart, and thyroid autoimmunity 120 
with normal thyroid function. Additional diagnoses were benign monoclonal 121 
gammopathy and hypertension that had been treated until 2011 with hydrochlorothiazide. 122 
In June 2013, he had abdominal discomfort and his pancreatic enzyme levels were 50% 123 
above their reference values. However, an abdominal magnetic resonance imaging scan 124 
was normal. The symptoms disappeared and his pancreatic enzyme levels decreased, but 125 
did not completely normalise. Given the persistence of the abnormality the advice of a 126 
gastroenterologist was sought and the possibility of autoimmune pancreatitis was 127 
considered. At the end of follow-up, the patient was treated with insulin glargine and 128 




In both patients, AHH was suspected and analyses for the presence of CaSR antibodies 130 
were performed. The study was approved by the Ethical Committee of the Hospital de la 131 
Santa Creu I Sant Pau, Barcelona, Spain. Each patient had given written informed 132 
consent. 133 
CaSR immunoprecipitation assays 134 
CaSR immunoprecipitation assays used to detect CaSR antibodies were undertaken as 135 
detailed elsewhere (19). Briefly, human embryonic kidney 293 (HEK293) cells were 136 
transiently transfected with pcCaSR-FLAG (19). Cell extract containing expressed CaSR-137 
FLAG protein was then prepared and stored at -80°C. GammaBind® Sepharose beads 138 
(GE Healthcare, Little Chalfont, UK) were mixed with patient or control sera or with 139 
anti-CaSR antibody (Alpha Diagnostic International, San Antonio, TX, USA) at a 1:100 140 
dilution in immunoprecipitation buffer, and incubated at 4°C for 1 h. Subsequently, the 141 
beads and antibody complexes were collected and incubated with cell extract containing 142 
CaSR-FLAG protein for 16 h at 4°C. The bead-antibody-CaSR-FLAG protein complexes 143 
were then collected and subjected to SDS-PAGE and immunoblotting using anti-FLAG® 144 
M2-Peroxidase Conjugate (Sigma-Aldrich, Poole, UK) and an ECL™ Western Blotting 145 
Analysis System (GE Healthcare). The densitometry of bands on developed films 146 
resulting from immunoprecipitated CaSR-FLAG protein was performed in a Bio-Rad GS 147 
690 Scanning Densitometer with Multi-Analyst Software (Bio-Rad Laboratories Ltd., 148 
Hemel Hempstead, UK). 149 
A CaSR antibody index for each serum sample was calculated as the densitometry value 150 




duplicate in three separate experiments and its mean CaSR antibody index calculated. 152 
The upper normal limit for the assay was calculated using the CaSR antibody index + 153 
3SD of 10 controls. Any serum with a CaSR antibody index above the upper limit of 154 
normal was designated as positive for CaSR antibodies. 155 
Antibody purification 156 
IgG was isolated from sera using protein G Sepharose 4 Fast Flow (GE Healthcare) 157 
affinity chromatography, according to the manufacturer’s instructions (20). Antibodies 158 
against a specific CaSR peptide were isolated by affinity chromatography using a 159 
CarboxyLink Immobilization Kit (Thermo Fisher Scientific, Waltham, MA, USA) (20). 160 
All purified antibodies were dialysed, concentrated, and stored at –20°C at 10 mg/ml. 161 
CaSR peptide ELISAs 162 
CaSR peptide ELISAs to identify CaSR antibody binding sites were carried out as 163 
detailed previously (20). The peptides (Cambridge Peptides, Birmingham, UK) used 164 
represented amino acid residues 41-69, 114-126, 171-195, 344-358, and 374-391 of the 165 
CaSR sequence. In brief, 20 ng of the required peptide were applied to the wells of a 96-166 
well microtiter plate overnight at 4°C. Plate wells were blocked with blocking buffer 167 
(PBS containing 0.1% Tween 20 and 3% BSA) for 30 min at 37°C, and washed with PBS 168 
containing 0.1% Tween 20. Patient and control sera were added to wells at a 1:100 169 
dilution and incubated at room temperature for 1 h before washing. Antibody binding was 170 
detected using anti-human IgG conjugated to alkaline phosphatase (Sigma-Aldrich) and 171 
alkaline phosphatase substrate SIGMAFAST p-Nitrophenyl phosphate (Sigma-Aldrich) 172 




A CaSR antibody index for each serum sample was calculated as the OD405 of the tested 174 
serum/mean OD405 value of 20 control sera. For each ELISA, sera were tested in 175 
triplicate in three separate experiments and their mean CaSR peptide antibody indices 176 
calculated. The upper limit of normal for each CaSR peptide ELISA was calculated using 177 
the mean CaSR peptide antibody index + 3SD of 20 healthy control sera. Any serum with 178 
a CaSR peptide antibody index above the upper limit of normal was designated as 179 
positive for antibodies against the CaSR peptide tested. 180 
To estimate CaSR antibody titres, the patients’ sera were analysed at dilutions of 1:100 181 
upto 1:10,000. Titres were defined as the serum dilution at which antibody binding was 182 
detected above the upper limit of normal for the ELISA. To determine CaSR antibody 183 
IgG subtype, anti-human IgG1, IgG2, IgG3, and IgG4 alkaline phosphatase conjugates 184 
(SouthernBiotech, Birmingham, AL, USA) were applied as the secondary antibodies. 185 
Intracellular inositol-1-phosphate accumulation assay 186 
The response of mammalian HEK293 cells stably expressing the CaSR (HEK293-CaSR) 187 
to calcium was assessed by measuring intracellular inositol-1-phosphate (IP1) 188 
accumulation, as described elsewhere (20). For investigating the functional effects of 189 
CaSR antibodies, monolayer HEK293-CaSR cells were preincubated for 10 min at 37°C 190 
with the patients’ purified CaSR antibodies or control IgG at a 1:100 dilution in calcium-191 
free assay buffer containing 10 mM lithium chloride. The cells were then stimulated with 192 
0.5-5 mM calcium chloride for 60 min at 37°C. HEK293-CaSR cells without 193 




30 min at 37°C with 50 μl of 2.5% IP-One ELISA Kit Lysis Reagent (CIS Bio 195 
International, Gif-sur-Yvette, France). 196 
The accumulation of IP1 in the recovered cell lysates was assessed using an IP-One 197 
ELISA Kit (CIS Bio International), according to the manufacturer’s protocol. The IP-One 198 
ELISA was based on competition between free IP1 and an IP1-horseradish peroxidase 199 
(HRP) conjugate for binding to an anti-IP1 monoclonal antibody. Therefore, any increase 200 
in IP1 in the HEK293-CaSR cells following calcium-stimulation was reflected by a 201 
decrease in IP1-HRP binding. The results for IP1 accumulation were expressed as: 202 
percentage inhibition of IP1-HRP binding = [1 - IP1-HRP binding in stimulated cells/IP1-203 
HRP binding in unstimulated cells] x 100. Each CaSR antibody was tested in six separate 204 
experiments and the mean percentage inhibition of IP1-HRP binding calculated. At each 205 
calcium concentration (0.5-5 mM), the accumulation of IP1 was compared between 206 
HEK293-CaSR cells preincubated with CaSR antibody or control IgG and those not, 207 






Detection of CaSR antibodies in the patients’ serum 211 
Immunoprecipitation assays were used to detect CaSR antibodies in the patients’ sera.  212 
The upper limit of normal for the immunoprecipitation assay (mean CaSR antibody index 213 
+ 3SD of 10 control sera) was a CaSR antibody index of 2.72. Both patients had a CaSR 214 
antibody index (mean ± SD) above the upper normal limit at 25.6 ± 5.8 and 43.2 ± 7.2 for 215 
Patient 1 and 2, respectively, and were therefore considered antibody-positive (Figure 2). 216 
Identification of CaSR antibody epitopes 217 
Peptides representing previously identified CaSR epitopes at amino residues 41–69, 114–218 
126, and 171–195, 344-358 and 374-391 (12, 13, 21) were used in ELISAs to identify the 219 
binding sites of the patients’ receptor antibodies. Antibody reactivity against epitope 41-220 
69 was detected in both patients (Table 1). An antibody response against epitope 114-126 221 
was apparent in patient 1 and 2 (Table 1). No antibody response was detected against 222 
CaSR peptides 171-195, 344-358 or 374-391 (Table 1). 223 
CaSR antibody titres and subclass 224 
Antibody titres against each relevant epitope were again investigated in CaSR peptide 225 
ELISAs. Titres were 1:1000 for antibodies against epitope 41–69 (Patient 1 and 2), 226 
1:5000 against 114-126 (Patient 1), and 1:10,000 against 114-126 (Patient 2). Following 227 
purification of the patients’ CaSR antibodies using affinity chromatography, ELISAs 228 




CaSR epitope 41–69 were of the IgG1 subclass, and that antibodies against 114–126 were 230 
of subclass IgG1 or IgG3 (Table 2). 231 
Functional effects of CaSR antibodies 232 
The effects of the patients’ CaSR antibodies on calcium-stimulation of the receptor were 233 
analysed by preincubation of HEK293-CaSR cells with CaSR antibody samples prior to 234 
stimulating with calcium. The accumulation of intracellular IP1 was assessed as the 235 
indicator of CaSR-stimulation. The results indicated that preincubation of HEK293-CaSR 236 
cells with antibodies against CaSR epitope 41-69 (Patient 1 and 2) did not affect IP1 237 
accumulation (data not shown). Preincubation with antibodies against epitope 114–126 238 
(Patient 1 and 2) resulted in a statistically significant decrease in IP1 accumulation upon 239 
calcium-stimulation compared with calcium-stimulation alone at calcium concentrations 240 






Autoimmune hypocalciuric hypercalcemia mimics the biochemical pattern observed in 244 
patients with FHH, but is due to the presence of antibodies that inhibit the CaSR from 245 
reacting appropriately to elevated blood calcium levels (12-18). Here, two patients are 246 
presented with suspected AHH based on the presence of other autoimmune disorders, 247 
Hashimoto’s thyroiditis in one patient and LADA and thyroid autoimmunity in the other, 248 
along with the appearance of an acquired hypercalcemia with persistent hypocalciuria. In 249 
addition, neither patient had a personal or familial history of hypercalcemia, genetic 250 
mutations associated with FHH (9-11), nor hyperfunctioning parathyroid glands. Analysis 251 
of the patients’ sera using immunoprecipitation assays detected CaSR antibodies in both 252 
individuals supporting a diagnosis of AHH. 253 
Analysis of the CaSR antibody binding sites revealed one epitope at amino acids 41-69, 254 
which had been previously identified in patients with autoimmune hypoparathyroidism 255 
and one patient with AHH (20, 21). Interestingly, the epitope overlaps the CaSR loop1 256 
domain (amino acids 50-59) which, if deleted, reduces receptor activation (22, 23). 257 
However, functional analysis of the antibodies against the extracellular 41-69 epitope 258 
were found to have no detectable effect upon CaSR activity. This finding is in accordance 259 
with previous reports of CaSR antibodies that bind to this site, albeit they were from 260 
patients with autoimmune hypoparathyroidism (20). 261 
The epitope at amino acids 114-126 overlaps the CaSR loop 2 domain (amino acids 117-262 
136). Deletion of the loop 2 domain or point mutations present within this region can 263 
increase the sensitivity of the CaSR to calcium and can cause autosomal dominant 264 




the receptor have been identified in patients with autoimmune hypoparathyroidism (20). 266 
In the present study, the patients’ antibodies against the CaSR 114-126 epitope 267 
demonstrated receptor-blocking activity such that even at raised blood calcium, PTH 268 
would still be secreted from the parathyroid due to a right-shift of the CaSR’s set point. In 269 
view of the contrasting results, antibody binding to the epitope could either activate or 270 
inhibit the receptor, depending on whether binding of the specific antibody favoured the 271 
active or inactive conformation(s), respectively. 272 
Antibodies against epitopes at amino acids 214-236, 374-391, and 344-358 of the CaSR, 273 
which have previously been reported in patients with AHH (12, 13), were not identified 274 
in the present study. Similar results to those here have been reported for an AHH patient 275 
with CaSR antibodies in that no antibodies against CaSR peptides 214-236, 374-391 and 276 
344-358 were detected in this individual (14). 277 
Previously, 11 patients with AHH have been described (12-18, 21). Two of these were 278 
unusual in that they were identified by family screening (12); the remaining cases appear 279 
to be sporadic. All 11 cases presented with usually mild and asymptomatic 280 
hypercalcemia, normal or decreased blood phosphate levels, and normal or elevated PTH 281 
values. Hypocalciuria was confirmed in some patients, but not always checked. In six 282 
patients, the serum PTH levels were at least 1.5 times above the reference range. This 283 
appears to be in contrast to FHH in which around 80% of patients have a serum PTH 284 
level within the reference range; the ratio of measured serum PTH level to the upper level 285 
of the reference range was 0.7 in a recent series of 65 FHH patients (24). In this series, 286 
the median age at diagnosis of FHH was 49 years and 68% of the patients were female. 287 




diagnosis was 66 years (age range, 18-82 years). Six patients had at least one associated 289 
autoimmune disorder: autoimmune thyroiditis occurred in three, with single cases of 290 
LADA, celiac disease, bullous pemphigoid, autoimmune hypophysitis, and rheumatoid 291 
arthritis. Three patients had anti-nuclear antibodies or perinuclear anti-neutrophil 292 
cytoplasmic antibodies. Our patients presented with similar characteristics to the 293 
previously described cases having mild and asymptomatic hypercalcemia, hypocalciuria, 294 
and the presence of other autoimmune diseases; one of the two patients had a greatly 295 
elevated PTH. Both patients were male, so that in the total of 13 cases now reported, the 296 
male:female sex ratio is 0.86.  297 
Although the frequency of AHH may be rare, it could be that cases of this disorder are 298 
misdiagnosed as having primary hyperparathyroidism or FHH (6-8). Determinant traits 299 
for the differentiation between these two conditions and AHH are the presence of new-300 
onset hypercalcemia, which is only possible if previously normal serum calcium levels 301 
are available, and hypocalciuria (6-8). Unlike FHH, most cases of AHH are sporadic and 302 
have an associated autoimmune disorder, but like FHH, AHH patients often have few or 303 
no symptoms. In contrast to FHH, the serum PTH level in AHH patients is often raised 304 
significantly.  305 
Neither of the two patients described in this study received treatment for their 306 
hypercalcemia. Parathyroidectomy was excluded in both cases in light of the suspicion of 307 
AHH and the futility of surgery in these cases as well as in other types of autoimmune 308 
hypercalcaemia (13, 18, 25). Treatment with glucocorticoids has been assessed in three 309 




CaSR could be a promising treatment of severe hypercalcemia as they act as stimulators 311 
of the CaSR, thus antagonising the effects of the receptor-blocking antibodies (15). 312 
In conclusion, AHH is to be suspected in patients with an acquired biochemical pattern of 313 
PTH-dependant hypocalciuric hypercalcemia, especially in those with other concomitant 314 
autoimmune diseases. Its suspicion may preclude from parathyroidectomy, and treatment 315 
with the calcimimetic drug cinacalcet should be considered in symptomatic cases. 316 
Diagnosis by means of detection of CaSR antibodies is not routinely implemented, but 317 
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Figure Legends 423 
Figure 1 424 
(A) Total serum calcium concentration and (B) urinary calcium:creatinine clearance ratio 425 
(UCCR) of Patient 1 and Patient 2 during the entire follow-up period. The shaded area 426 
shows in (A) the normal range for total serum calcium at 2.15-2.55 mmol/L and in (B) 427 
the normal range for UCCR at 0.01-0.02. 428 
Figure 2 429 
Assessment of patients’ sera for CaSR antibodies. Sera from Patient 1 and 2, and 10 430 
healthy controls were tested for CaSR-binding activity using an immunoprecipitation 431 
assay. (A) The upper limit of normal for the immunoprecipitation assay (mean CaSR 432 
antibody index + 3SD of 10 control sera) was a CaSR antibody index of 2.72. The results 433 
(mean CaSR antibody index ± SD) are shown for each patient serum sample tested in 434 
three separate experiments. The CaSR antibody index was 25.6 ± 5.8 and 43.2 ± 7.2 for 435 
Patient 1 and 2, respectively. (B) Immunoblots from the immunoprecipitation assay are 436 
shown for anti-CaSR antibody (Lane 1); Patient 1 serum (Lane 2); Patient 2 serum (Lane 437 
3); and a control serum (Lane 4).  438 
Figure 3 439 
Effect of patients’ CaSR antibodies on CaSR function. Intracellular IP1 accumulation in 440 
HEK293-CaSR cells was measured in response to stimulation by 0.5-5.0 mM calcium 441 
after they were preincubated with the patients’ CaSR antibody samples. Cells without 442 
preincubation with antibody and also preincubated with control IgG were also included. 443 




as: percentage inhibition of IP1-HRP binding = [1-IP1-HRP binding in stimulated 445 
cells/IP1-HRP binding in unstimulated cells] x 100. The results are shown for the 446 
patients’ CaSR antibodies tested in six separate experiments. When compared with 447 
HEK293-CaSR cells not preincubated with CaSR antibody, preincubation with the 448 
patients’ antibodies against epitope 114-126 decreased the levels of IP1 accumulation 449 
significantly in HEK293-CaSR cells at concentrations of 0.5, 1.5, and 3.0 mM calcium; P 450 





Table 1: Epitope identification for patient CaSR antibodies 453 
 454 
 




Upper limit of 








Patient 2 CaSR 
antibody index3 
 
CaSR 41-69  2.23 10.9  14.3  
CaSR 114-126  1.94 8.4  12.1  
CaSR 171-195  2.09 1.12  1.09  
CaSR 344-35  1.82 1.03  0.98  
CaSR 374-391  1.73 0.95  1.08  
 455 
 456 
1CaSR peptide ELISAs were used to identify CaSR antibody binding sites. 457 
2The upper limit of normal for each ELISA was calculated using the mean CaSR 458 
antibody index + 3SD of 20 controls. 459 
3The CaSR antibody index for each serum sample was calculated as the OD405 of the 460 
tested serum/mean OD405 value of 20 control sera. A CaSR antibody index (mean of 461 
three separate experiments) above the upper limit of normal for the ELISA indicated 462 











CaSR peptide used 





Upper limit of 








Patient 2 CaSR 
antibody index3 
 
CaSR 41-69/IgG1  1.84 9.1  15.3  
CaSR 41-69/IgG2  1.89 1.06  1.10  
CaSR 41-69/IgG3  1.78 1.23  0.98  
CaSR 41-69/IgG4  1.83 1.01  0.96  
CaSR 114-126/IgG1  1.72 10.6  1.03  
CaSR 114-126/IgG2  1.75 1.02  1.16  
CaSR 114-126/IgG3 1.91 1.12  16.8  




1To determine CaSR antibody IgG subclass, CaSR peptide ELISAs were used with anti-473 
human IgG1, IgG2, IgG3 or IgG4 alkaline phosphatase conjugates as the secondary 474 
antibody. 475 
2The upper limit of normal for each ELISA was calculated using the mean CaSR 476 
antibody index + 3SD of 20 controls.  477 
3The CaSR antibody index for each serum sample was calculated as the OD405 of the 478 
tested serum/mean OD405 value of 20 control sera. A CaSR antibody index (mean of 479 
three separate experiments) above the upper limit of normal for the ELISA indicated 480 





























Figure 3 495 
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